XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Equity Incentive Plans (Tables)
 6 Months Ended
Mar. 31, 2024
Equity Incentive Plans [Abstract]  
Summary of Activity in the Company's RSUs A summary of activity in the Company’s RSUs for the six months ended March 31, 2024 is as follows:
 

Number of
units

  

Weighted-
Average
Grant Date
Fair Value
per Unit

Outstanding at September 30, 2023

  

209,494

 

  

$

6.84

Performance-based RSUs

  

3,999,999

 

  

$

8.65

Vested

  

(130,934

)

  

$

6.84

Outstanding at March 31, 2024

  

4,078,559

 

  

$

8.61
Schedule of Stock Option Activity Stock option activity for the six months ended March 31, 2024 is as follows:
 

Number of
Options

  

Weighted-
Average
Exercise
Price
per Share

  

Weighted-
Average
Remaining
Contractual
Term (years)

Outstanding at September 30, 2023

  

5,905,684

 

  

$

4.28

    

Granted

  

32,200

 

  

$

6.84

    

Exercised

  

(474,313

)

  

$

5.91

    

Forfeited

  

(941,042

)

  

$

6.53

    

Outstanding at March 31, 2024

  

4,522,529

 

  

$

3.66

  

6.3

Exercisable at March 31, 2024

  

4,041,704

 

  

$

3.29

  

6.1
Schedule of Weighted-Average Grant Date Fair Value of Options Granted The fair value of stock options granted was estimated with the following assumptions:
 

Six months ended March 31,
   

2024

  

2023
   

Range

  

Range
   

Low

  

High

  

Low

  

High

Expected volatility

  

54.8

%

  

55.6

%

  

52.4

%

  

53.6

%

Expected dividend yield

  

0

%

  

0

%

  

0

%

  

0

%

Risk-free interest rate

  

3.9

%

  

4.4

%

  

3.6

%

  

4.2

%

Expected term (years)

  

4.5

 

  

5.3

 

  

5.0

 

  

5.8

 
Schedule of Consolidated Statements of Operations and Comprehensive Loss Include Stock-Based Compensation Expense The condensed consolidated statements of operations and comprehensive loss include stock-based compensation expense as follows:
 

Three months ended
March 31,

  

Six months ended
March 31,
   

2024

  

2023

  

2024

  

2023

Cost of revenue

  

$

—

  

$

11

  

$

—

  

$

22

Research and development

  

 

274

  

 

541

  

 

775

  

 

1,083

Selling, general and administrative

  

 

1,167

  

 

5,227

  

 

13,371

  

 

8,530

Total stock-based compensation expense

  

$

1,441

  

$

5,779

  

$

14,146

  

$

9,635